Lv4
480 积分 2020-04-13 加入
A phase II, randomized, double-blind study of the use of rucaparib versus placebo maintenance therapy in metastatic and recurrent endometrial cancer
1天前
待确认
Efficacy of sintilimab plus bevacizumab in recurrent/persistent ovarian clear cell carcinoma (INOVA): A multicenter, single-arm, phase II trial
1个月前
已完结
产前和产时电子胎心监护临床实践专家共识
8个月前
已完结
The next chapter in immunotherapy and radiation combination therapy – cancer-specific perspectives
1年前
已完结
Menopause guideline appraisal and algorithm development for premature ovarian insufficiency
1年前
已完结
Management of menopause: a view towards prevention
1年前
已完结
The 2022 hormone therapy position statement of The North American Menopause Society: no news is good news
1年前
已关闭
Diabetes in Menopause: Risks and Management
1年前
已完结
Premature ovarian insufficiency: an International Menopause Society White Paper
1年前
已完结
The 2022 hormone therapy position statement of The North American Menopause Society: no news is good news
1年前
已完结
皖公网安备34019202002308
